active
Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)
Offered by National Institutes of Health (NIH)
Key Details
Deadline Sunday, 16 October 2016
Award Amount $275,000 directs only
Host Country United States
Years Since PhD New Investigators, who have not received independent NIH funding, and investigators who are new to PID research are especially encouraged to apply to this FOA.
Additional Information
Comments This FOA will support innovative exploratory/developmental investigations in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for, primary immunodeficiency diseases. Direct costs are limited to $275,000 over the two-year project period, with no more than $200,000 in direct costs allowed in any single year. Applicants may request direct costs in $25,000 modules.
About the Funder
Record Information
Last Verified 19 February 2026 by asntech
Last Updated December 2018
Source legacy-import